Recombinant Influenza Vaccine Vs Standard Dose Inactivated Influenza Vaccine Elicits More Robust Humoral Immune Responses To Several Vaccine Viruses, Study Finds

Infectious Disease Advisor (11/22, Basilio) reported, “A recombinant influenza vaccine [RIV] vs standard dose inactivated influenza vaccine [SD IIV] elicited more robust humoral immune responses to several vaccine viruses at 1 and 6 months, according to study results.” The researchers said, “Relative VE of RIV compared to SD IIV did not reach statistical significance but RIV elicited more robust humoral immune responses to 2 of 4 vaccine viruses at 1-month and 3 of 4 viruses at 6-months after vaccination suggesting possible improved and sustained immune protection from RIV.” The findings were published in Open Forum Infectious Diseases.